We have insufficient knowledge of what proportion of patients at any one time will have a BP level above the target value, even when guidelines have been closely followed and adherence has been high. In a post hoc analysis of a large RCTof essential hypertension, a single elevated office BP reading in a patient with previously well controlled BP was unlikely to indicate a persistent loss of BP control, but rather reflect day-to-day DISCLAIMER While every effort is made by the publishers, editorial board, and ISN to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contri- butor, copyright holder, or advertiser concerned. Accord- ingly, the publishers and the ISN, the editorial board and their respective employers, office and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer s own published literature. Methods for guideline development AIM The overall aim of this project was to develop an evidence- based CPG for the use of BP-lowering agents in individuals with CKD. The guideline consists of recommendation statements, rationale, and a summary of systematically generated evidence on relevant pre-defined clinical topics. OVERVIEW OF PROCESS The development process for the KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease included the following steps: K Appointing Work Group members and the ERT. K Discussing process, methods, and results. 